{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:10:13Z","timestamp":1790331013217,"version":"4.1.0"},"reference-count":4,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"DOI":"10.1002\/cpt.70495","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:51:35Z","timestamp":1790329895000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to \u201cUnderstanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis\u201d"],"prefix":"10.1002","author":[{"given":"Joachim","family":"Almquist","sequence":"first","affiliation":[{"name":"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Lin","family":"Chia","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bertagnolli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Cambridge  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-1569","authenticated-orcid":false,"given":"Weifeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Late Respiratory and Immunology BioPharmaceuticals R&D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_2_2_1_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/cpt.70307","article-title":"Anifrolumab dose regimen selection for a phase 3 trial in lupus nephritis","volume":"120","author":"Almquist J.","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_2_2_1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne D.","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_2_3_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon\u2013a receptor monoclonal antibody, in moderate\u2010to\u2010severe systemic lupus erythematosus","volume":"69","author":"Furie R.","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"e_1_2_2_4_1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/bioinformatics\/btp358","article-title":"Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood","volume":"25","author":"Raue A.","year":"2009","journal-title":"Bioinformatics"}],"container-title":["Clinical Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:51:36Z","timestamp":1790329896000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":4,"alternative-id":["10.1002\/cpt.70495"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70495","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cpt.70495"}}